Landec Corporation  

(Public, NASDAQ:LNDC)   Watch this stock  
Find more results for LNDC
-0.15 (-1.08%)
Real-time:   10:19AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.50 - 13.80
52 week 11.20 - 14.95
Open 13.80
Vol / Avg. 10,515.00/57,726.00
Mkt cap 378.22M
P/E 44.47
Div/yield     -
EPS 0.31
Shares 27.53M
Beta 1.04
Inst. own 94%
Apr 2, 2018
Q3 2018 Landec Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jan 9, 2018
Landec Corp at ICR Conference
Jan 4, 2018
Q2 2018 Landec Corp Earnings Call - Webcast
Jan 3, 2018
Q2 2018 Landec Corp Earnings Release
Dec 6, 2017
Landec Corp at ROTH Utah Active & Healthy Lifestyle Corp Access Event
More events from DailyFinance »    

Key stats and ratios

Q4 (Nov '17) 2017
Net profit margin 0.38% 2.01%
Operating margin -0.41% 2.68%
EBITD margin - 5.40%
Return on average assets 0.55% 3.05%
Return on average equity 0.85% 4.84%
Employees 670 -
CDP Score - -


5201 Great America Pkwy Ste 232
SANTA CLARA, CA 95054-1126
United States - Map
+1-650-3061650 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Landec Corporation designs, develops, manufactures and sells a range of health and wellness products for food and biomaterials markets. The Company licenses technology applications to partners. The Company operates through three segments: Packaged Fresh Vegetables, Food Export and Biomaterials. The Packaged Fresh Vegetables segment markets and packs specialty packaged whole and fresh-cut fruit and vegetables, the majority of which incorporate the BreatheWay specialty packaging for the retail grocery, club store and food services industry. The Food Export segment is engaged in the purchase and sale of whole commodity fruit and vegetable products primarily to Asia. The Biomaterials segment sells products utilizing hyaluronan, a polysaccharide that is distributed in the extracellular matrix of connective tissues in both animals and humans, and non-hyaluronan (HA) products for medical use primarily in the ophthalmic, orthopedic and other markets.

Officers and directors

Steven D. Goldby Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Molly A. Hemmeter President, Chief Executive Officer
Age: 49
Bio & Compensation  - Reuters
Gregory S. Skinner Chief Financial Officer, Vice President - Finance and Administration
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James G. Hall President of Lifecore
Age: 53
Bio & Compensation  - Reuters
Ronald Lane Midyett Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Steven P. Bitler Ph.D. Vice President - Corporate Technology
Age: 58
Bio & Compensation  - Reuters
Deborah D. Carosella Director
Bio & Compensation  - Reuters
Albert D. Bolles Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Frederick Frank Independent Director
Age: 84
Bio & Compensation  - Reuters
Tonia Pankopf Independent Director
Age: 48
Bio & Compensation  - Reuters